Evidence map›Paper›PMID 40032011›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

Transdermal delivery of ultradeformable cationic liposomes complexed with miR211-5p (UCL-211) stabilizes BRAFV600E+ melanocytic nevi.

Tanya Chhibber, Michael T Scherzer, Anastasia Prokofyeva, Carly Becker, Rebecca Goldstein Zitnay, Eric Smith, Nitish Khurana, Mikhail Skliar, Dekker C Deacon, Matthew W VanBrocklin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tanya ChhibberDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, USA.
Michael T ScherzerHuntsman Cancer Institute, Salt Lake City, UT, USA.
Anastasia ProkofyevaHuntsman Cancer Institute, Salt Lake City, UT, USA.
Carly BeckerHuntsman Cancer Institute, Salt Lake City, UT, USA; Department of Dermatology, University of Utah, Salt Lake City, UT, USA.
Rebecca Goldstein ZitnayHuntsman Cancer Institute, Salt Lake City, UT, USA.
Eric SmithDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
Nitish KhuranaDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, USA.
Mikhail SkliarDepartment of Chemical Engineering, University of Utah, Salt Lake City, UT, USA.
Dekker C DeaconHuntsman Cancer Institute, Salt Lake City, UT, USA; Department of Dermatology, University of Utah, Salt Lake City, UT, USA.
Matthew W VanBrocklinHuntsman Cancer Institute, Salt Lake City, UT, USA; Department of Surgery, University of Utah, Salt Lake City, UT, USA.
Hamidreza GhandehariDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, USA; Huntsman Cancer Institute, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. Electronic address: hamid.ghandehari@pharm.utah.edu.
Robert L Judson-TorresHuntsman Cancer Institute, Salt Lake City, UT, USA; Department of Dermatology, University of Utah, Salt Lake City, UT, USA; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA. Electronic address: robert.judson-torres@hci.utah.edu.
Paris JafariDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA; Utah Center for Nanomedicine, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: paris.jafari@unil.ch.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Nevus associated microRNAs as mediators of BRAF-induced growth arrest and biomarkers of melanoma progressionR01CA229896 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JUDSON-TORRES, ROBERT LAIRD · 2021 to 2025
$1.8M
Amnis ImageStreamX MarkII Imaging Flow CytometerS10OD026959 · OD · UNIVERSITY OF UTAH · PI MARVIN, JAMES E · 2020 to 2020
$517k
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA229896NIH HHS S10 OD026959
6 · The paper itself

Abstract

Small non-coding RNAs (e.g., siRNA, miRNA) are involved in a variety of melanocyte-associated skin conditions and act as drivers for alterations in gene expression within melanocytes. These molecular changes can potentially affect the cellular stability of melanocytes and promote their oncogenic transformation. Thus, small RNAs can be considered as therapeutic targets for these conditions, however, their transdermal delivery to the melanocytes through the epidermal barrier is challenging. We synthesized and extensively evaluated ultradeformable cationic liposome (UCLs) carriers complexed with synthetic microRNAs (miR211-5p; UCL-211) for transdermal delivery to melanocytes. UCL-211 complexes were characterized for their physicochemical properties, encapsulation efficiency, and deformability, which revealed a significant advantage over conventional liposomal carriers. Increased expression of miR211-5p stabilizes melanocytic nevi and keeps them in a growth-arrested state. We did a comprehensive assessment of cellular delivery, and biological activity of the miR211-5p carried by UCL-211 in vitro and their permeation through the epidermis of intact skin using ex vivo human skin tissue explants. We also demonstrated, in vivo, that transdermal delivery of miR211-5p by topical application of UCL-211 stabilized BRAFV600E+ nevi melanocytes in a benign nevi state.

Indexed as

MicroRNAsNevus, PigmentedProto-Oncogene Proteins B-rafSkin NeoplasmsAdministration, CutaneousAnimalsCationsFemaleHumansLiposomesMelanocytesSkinBRAF protein, humanCationsLiposomesMicroRNAsProto-Oncogene Proteins B-rafMelanocytesMelanocytic nevimiRNA deliveryTransdermal deliveryUltradeformable cationic liposomes

Identifiers

PMID40032011
PMCPMC12016659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.